Intepirdine

Sep 26, 2017

Axovant Announces Negative Topline Results of Intepirdine Phase 3 MINDSET Trial in Alzheimer's Disease

Sep 26, 2017

Roivant Sciences Statement on MINDSET Results

Aug 07, 2017

Axovant Announces Fiscal First Quarter Financial Results and Corporate Updates

Jun 19, 2017

FDA Grants Fast Track Designation to Axovant's Nelotanserin for Visual Hallucinations in Dementia with Lewy Bodies

Jun 13, 2017

Axovant Sciences Announces Fiscal Year-End Financial Results and Corporate Updates

Jun 06, 2017

Axovant Strengthens Executive Team with Key Management Appointments

Jun 06, 2017

Axovant Announces Changes to Board of Directors